Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB123667 in Advanced Solid Tumors
NCT05238922Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of INCB123667 in solid tumor (21 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at Day 28, Treatment Emergent Adverse Events at 12 months and 3 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
INCB123667
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05238922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238922.